Cannabis Science Inc (OTCMKTS:CBIS) has jolted up another +15% to begin the week. CBIS like other cannabis stocks took a bit of a step back after comments from Jeff Sessions, but investor confidence is returning to the cannabis sector especially for a stock like CBIS that is combining technology and cannabis into a unique vision. CBIS will implement two pharmacies in concentrated areas that are managed through automation. The stock is near 6-month highs right now and continues to march toward 52-week highs.
“Cannabis Science’s Pharmacies are in prime, high traffic areas on Pico Boulevard in Los Angeles and on Ventura Boulevard in the San Fernando Valley. The Company has also been presented with an opportunity to purchase a potentially 60,000 sq. ft. building in Los Angeles, CA. This is where the Company can build its first Cannabis Science Medical Center, including full laboratory facilities, patient intake, and doctor and nurse clinics. We will look at the possible use of the Company’s rare U.S. Federal Government Cage Code Clearance to provide U.S. Federal Government approved Emergency Medical Services,” stated Mr. Raymond C. Dabney, CBIS’ President, CEO, and Co-founder.
Cannabis Science Inc (OTCMKTS:CBIS) defines itself according to the narrative of a leading-edge researcher and designer of cannabinoid solutions to health problems.
CBIS is involved in developing medicines for autism, blood pressure, cancer and cancer side effects, as well as for other illnesses comprising for general health maintenance. It also develops CS-TATI-1 for newly diagnosed and treatment-experienced patients with drug-resistant HIV strains, as well as those intolerant of available therapies; CS-S/BCC-1 to treat basal and squamous cell carcinomas; and a proprietary cannabis-based therapy for neurological conditions.
In addition, CBIS offers an online video-based medical cannabis education system, including courses, such as medical cannabis law, medical marijuana, cooking, horticulture, and bud tending; and manufactures and distributes specialty horse and pet grooming and topical applications. It has a license agreement with Apothecary Genetics Investments LLC to produce various brand formulations for California medical cannabis market.
Find out when $CBIS stock reaches critical levels. Subscribe to OracleDispatch.com Right Now by entering your Email in the box below.
“It is possible we will include our sister Company, Crown Baus Capital Corp (OTC: CBCA) in this purchase. Additional space will be leased to physician groups and other medical cannabinoid related health services and well-being providers. I am particularly excited about the Cannabis Science Medical Center, this was always one of our main goals,” stated Mr. Dabney. “This facility will serve as a hub for our activities. Not only will physicians be able to consult directly with patients at the Center, but the Company will also be able to coordinate and expand its global reach and research on cannabinoid-based drugs related to development initiatives through the Cannabis Science Global Research Consortium.
“Our Pharmacies are designed to be state of the art facilities and they will be beautiful. We will showcase the entire Cannabis Science product line, as well as additional products from select vendors that meet the high standards that we have set for our CBIS-branded products,” stated Mr. Dabney. “As part of the Company’s overall drug-development strategy, the Cannabis Science Pharmacies will provide our Company with an important retail sales channel and allow us to interact directly with those who will benefit from our medicines – our patients.”
According to the company, these new acquisitions offer CBIS a very strong foothold in the medical services industry. In addition, the Company is actively negotiating with its East Coast Associates in Washington, D.C and New York City to expand the CBIS-branded Pharmacies into those areas.
Earning a current market cap value of $296.23M, CBIS is starting to roll out its full business plan as legalization commences in California. The state is shaping up to be the biggest cannabis stomping ground in the world and there is plenty of money to be made. CBIS has a nice retail channel and we expect revenue increases for Q1. Sign-up for continuing coverage on shares of $CBIS stock, as well as other hot stock picks, get our free newsletter today and get our next breakout pick!
Disclosure: we hold no position in $CBIS, either long or short, and we have not been compensated for this article.